Evidence map›Paper›PMID 37649617›Full record

ArticleVaccine: X2023

Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership.

Andrea A Berry, Ashley H Tjaden, Jone Renteria, DeAnna Friedman-Klabanoff, Amy N Hinkelman, Michael A Gibbs, Amina Ahmed, Michael S Runyon, John Schieffelin, Robert P Santos and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04342884 (A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04342884 completednot on this map

A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records

TypeobservationalSponsorWake Forest University Health SciencesRan2020 to 2022Enrolled61,410ConditionsCoronavirus, COVID
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Andrea A BerryDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Ashley H TjadenThe Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
Jone RenteriaThe Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
DeAnna Friedman-KlabanoffDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Amy N HinkelmanJerry M. Wallace School of Osteopathic Medicine, Campbell University, Lillington, NC, USA.
Michael A GibbsAtrium Health, Charlotte, NC, USA.
Amina AhmedAtrium Health, Charlotte, NC, USA.
Michael S RunyonAtrium Health, Charlotte, NC, USA.
John SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Robert P SantosUniversity of Mississippi Medical Center, Jackson, MS, USA.
Richard OberhelmanDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Matthew BottThe Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
Adolfo CorreaUniversity of Mississippi Medical Center, Jackson, MS, USA.
Sharon L EdelsteinThe Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
Diane UschnerThe Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
Thomas F WierzbaSection on Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA.
COVID-19 Community Research Partnership

Funding

Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
NIAID NIH HHS K23 AI125720
6 · The paper itself

Abstract

Introduction: High levels of immunity to SARS-CoV-2 in the community correlate with protection from COVID-19 illness. Measuring COVID-19 antibody seroprevalence and persistence may elucidate the level and length of protection afforded by vaccination and infection within a population. Methods: We measured the duration of detectable anti-spike antibodies following COVID-19 vaccination in a multistate, longitudinal cohort study of almost 13,000 adults who completed daily surveys and submitted monthly dried blood spots collected at home. Results: Overall, anti-spike antibodies persisted up to 284 days of follow-up with seroreversion occurring in only 2.4% of the study population. In adjusted analyses, risk of seroreversion increased with age (adults aged 55-64: adjusted hazard ratio [aHR] 2.19 [95% confidence interval (CI): 1.22, 3.92] and adults aged > 65: aHR 3.59 [95% CI: 2.07, 6.20] compared to adults aged 18-39). Adults with diabetes had a higher risk of seroreversion versus nondiabetics (aHR 1.77 [95% CI: 1.29, 2.44]). Decreased risk of seroreversion was shown for non-Hispanic Black versus non-Hispanic White (aHR 0.32 [95% CI: 0.13, 0.79]); college degree earners versus no college degree (aHR 0.61 [95% CI: 0.46, 0.81]); and those who received Moderna mRNA-1273 vaccine versus Pfizer-BioNTech BNT162b2 (aHR 0.35 [95% CI: 0.26, 0.47]). An interaction between healthcare worker occupation and sex was detected, with seroreversion increased among male, non-healthcare workers. Conclusion: We established that a remote, longitudinal, multi-site study can reliably detect antibody durability following COVID-19 vaccination. The survey platform and measurement of antibody response using at-home collection at convenient intervals allowed us to explore sociodemographic factors and comorbidities and identify predictors of antibody persistence, which has been demonstrated to correlate with protection against disease. Our findings may help inform public health interventions and policies to protect those at highest risk for severe illness and assist in determining the optimal timing of booster doses.Clinical trials registry: NCT04342884.

Indexed as

Antibody responsesCOVID-19COVID-19 vaccinesSARS-CoV-2Serology

Identifiers

PMID37649617
PMCPMC10462856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.